Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis
This study is not yet open for participant recruitment.
Verified by Hadassah Medical Organization, September 2007
Sponsored by: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00532519
  Purpose

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.


Condition Intervention
Prurigo Nodularis
Drug: citalopram (cipralex)

Drug Information available for: Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate Serotonin
U.S. FDA Resources
Study Type: Interventional
Study Design: Open Label, Single Group Assignment

Further study details as provided by Hadassah Medical Organization:

Intervention Details:
    Drug: citalopram (cipralex)
    10-20 mg/day, for 12 weeks.
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

Exclusion Criteria:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532519

Contacts
Contact: Liran Horev, MD OO97226777111 LIRAN_CH@BEZEQINT.NET

Locations
Israel
: Hadassah Medical Organization,
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: liran horev, md Hadassah Medical Organization, Jerusalem, Israel
Principal Investigator: rena cooper-kazaz, md Hadassah-Hebrew University Medical Center
  More Information

Study ID Numbers: horcoop-hmo-ctil
Study First Received: September 19, 2007
Last Updated: September 19, 2007
ClinicalTrials.gov Identifier: NCT00532519  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:
Skin Diseases
Skin Diseases, Eczematous
Dexetimide
Neurodermatitis
Citalopram
Prurigo nodularis
Serotonin
Dermatitis
Prurigo

Additional relevant MeSH terms:
Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Cholinergic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Muscarinic Antagonists
Serotonin Agents
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on January 16, 2009